Medial Temporal Atrophy Alone is Insufficient to Predict Underlying Alzheimer's Disease Pathology

Korean journal of family medicine
Hyo Eun JeongDuk-Chul Lee

Abstract

The medial temporal region is the earliest affected structure in patients with Alzheimer's disease (AD), and its atrophy is known as the hallmark of AD. This study aimed to investigate the value of medial temporal atrophy (MTA) for detecting 18F-florbetaben positron emission tomography (PET)-proven AD pathology. We retrospectively enrolled 265 subjects complaining of cognitive decline at a dementia outpatient clinic from March 2015 to December 2017. All subjects underwent brain magnetic resonance imaging, 18F-fluorodeoxyglucose PET, and 18F-florbetaben PET at baseline. We performed multivariable logistic regression analyses on variables including age, sex, years of education, white matter hyperintensities, apolipoprotein E (APOE) genotype, and memory composite scores in various combinations to investigate whether MTA was indicative of underlying AD pathology. Our sample population of 265 patients comprised 121 with AD-related cognitive impairment, 42 with Lewy bodies-related cognitive impairment, 32 with vascular cognitive impairment, and 70 with other or undetermined pathologies. In the multivariable logistic regression analyses, MTA was not an independent predictor of underlying AD pathology (P>0.200). The predictive power of...Continue Reading

References

Aug 1, 1987·AJR. American Journal of Roentgenology·F FazekasR A Zimmerman
May 1, 1995·Neurobiology of Aging·H Braak, E Braak
May 2, 2002·European Journal of Gastroenterology & Hepatology·Henrik SjövallMohammed Hassan-Alin
Aug 25, 2004·Journal of Internal Medicine·R C Petersen
Jan 9, 2007·Neurobiology of Aging·Niki S M SchoonenboomPhilip Scheltens
Apr 25, 2008·European Psychiatry : the Journal of the Association of European Psychiatrists·Khaled Abdulrab, Reinhard Heun
Aug 8, 2009·Neurobiology of Aging·Susan M LandauUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jan 20, 2010·Lancet Neurology·Clifford R JackJohn Q Trojanowski
Apr 5, 2012·Cold Spring Harbor Perspectives in Medicine·Sandra WeintraubDavid P Salmon
Feb 5, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Annapaola PrestiaUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 23, 2013·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Young NohDuk L Na
Oct 15, 2013·Journal of Internal Medicine·J B PereiraUNKNOWN AddNeuroMed consortium and for the Alzheimer's Disease Neuroimaging Initiative
May 14, 2014·Annual Review of Neuroscience·Jin-Tai YuJohn Hardy
Jun 28, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Kevin T OngChristopher C Rowe
Mar 6, 2015·Clinical and Translational Imaging : Reviews in Nuclear Medicine and Molecular Imaging·Osama SabriHenryk Barthel
Nov 29, 2015·European Journal of Nuclear Medicine and Molecular Imaging·Elizabeth MorrisStephen Keevil
Mar 5, 2016·Brain : a Journal of Neurology·Lorna HarperJonathan M Schott
Dec 28, 2016·Psychiatry Research. Neuroimaging·Carola G SchipkeOliver Peters

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

SPSS

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.